| Symbol | GNTA |
|---|---|
| Name | GENENTA SCIENCE S.P.A. |
| Sector | HEALTH CARE |
| Region | Europe |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | VIA OLGETTINA NO. 58, MILAN, 20132, Italy |
| Telephone | +39 22643468120 |
| Fax | — |
| — | |
| Website | https://www.genenta.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001838716 |
| Description | Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The companys product under development includes Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain, and TEMs -Immuno-Gene Therapy. Additional info from NASDAQ: |
New Form SCHEDULE 13D - Genenta Science S.p.A. <b>Filed:</b> 2026-05-05 <b>AccNo:</b> 0001493152-26-021319 <b>Size:</b> 133 KB
Read moreDirector Paracchi Pierluigi 🟢 acquired 100.0K shares (1 derivative) of Genenta Science S.p.A. (GNTA) at $0.63 Transaction Date: Mar 30, 2026 | Filing ID: 021237
Read moreNASDAQ traded attribute type Financial_Status was changed. Previous value: Normal. New value: Deficient.
Read moreNASDAQ symbol attribute type Financial_Status was changed. Previous value: Normal. New value: Deficient.
Read moreDirector Galimi Francesco 🟢 acquired 20.0K shares (1 derivative) of Genenta Science S.p.A. (GNTA) at $0.63 Transaction Date: Mar 30, 2026 | Filing ID: 014634
Read more